Gene therapy to halt rare form of sight loss – BBC News

Image caption Matthew Wood hopes the gene therapy will help him keep his remaining vision

A new gene therapy has been used to treat patients with a rare inherited eye disorder which causes blindness.

It's hoped the NHS treatment will halt sight loss and even improve vision.

Matthew Wood, 48, one of the first patients to receive the injection, told the BBC: "I value the remaining sight I have so if I can hold on to that it would be a big thing for me."

The treatment costs around 600,000 but NHS England has agreed a discounted price with the manufacturer Novartis.

Luxturna (voretigene neparvovec), has been approved by The National Institute for Health and Care Excellence (NICE), which estimates that just under 90 people in England will be eligible for the treatment.

The gene therapy is for patients who have retinal dystrophy as a result of inheriting a faulty copy of the RPE65 gene from both parents. The gene is important for providing the pigment that light sensitive cells need to absorb light. Initially this affects night vision but eventually, as the cells die, it can lead to complete blindness.

An injection is made into the back of the eye - this delivers working copies of the RPE65 gene. These are contained inside a harmless virus, which enables them to penetrate the retinal cells. Once inside the nucleus, the gene provides the instructions to make the RPE65 protein, which is essential for healthy vision.

Matthew Wood started losing his sight as a child, and is now registered blind. However, he does have some peripheral vision and can detect large objects and bright lights. He told the BBC: "Since I was a child I was continually told there was no treatment for this condition, so it's amazing to receive this gene therapy."

Mr Wood, from London, had his right eye treated during an hour-long operation at the John Radcliffe Hospital in Oxford.

His left eye will be injected in a few weeks. The surgery was carried out by Prof Robert MacLaren, who has pioneered research into gene therapies for preventing blindness.

He told the BBC: "This is very exciting - this is the first approved NHS gene therapy for an eye disease, but there are opportunities to use gene therapy to treat other diseases in future, not only in the eye."

The treatment is only suitable for patients who have some remaining vision. It should bring the biggest benefits to children with RPE65 retinal dystrophy, as it could halt sight loss before permanent damage is done.

It is not known how long the benefits of the treatment will last, but it's thought it could be several decades.

Jake Ternent, 23, from Durham, had his gene therapy at Moorfields Eye Hospital in London.

Like Matthew Wood, he is registered blind, but has some limited sight. He told the BBC: "I hope the treatment could improve my night vision, and possibly even my day vision, which would be incredible. I feel lucky and privileged to get this on the NHS."

Prof James Bainbridge - from Moorfields Eye Hospital - who treated Jake, told the BBC: "To be at the point now where we are able to offer this treatment on the NHS, is truly remarkable. This is the first example of what's anticipated to be a whole new generation of treatments."

It will take a month or two before Matthew and Jake know what changes the gene therapy has made to their vision. But even if it simply prevents further sight loss, both say they will be delighted.

Professor Stephen Powis, NHS medical director, said: "Loss of vision can have a devastating effect, particularly for children and young people, but this truly life-changing treatment offers hope to people with this rare and distressing condition."

Follow Fergus on Twitter.

Read more:

Gene therapy to halt rare form of sight loss - BBC News

With supply tight, Novartis readies gene therapy plant for production – BioPharma Dive

Supplies of Zolgensma, the gene therapy approved last year for spinal muscular atrophy, are tight.

Novartis, which sells the one-time treatment, can currently make about 700 to 800 doses a year at its manufacturing plant in Libertyville, Illinois. That's enough to cover the infants in the U.S. currently eligible to receive Zolgensma but leaves little room for treating a wider group of patients, which the Swiss drugmaker aims to do.

On Thursday, executives from AveXis, the Novartis unit that developed Zolgensma, opened a new facility in Durham, North Carolina, that the company views as a critical cog in its plans to expand supply of the gene therapy.

Initial production will begin this spring. But until the Food and Drug Administration licenses the plant, Novartis won't be able to use product made there for commercial sale. The company expects to gain approval next year.

Between now and then, Novartis also hopes to secure regulatory OKs for manufacturing Zolgensma at a site in Longmont, Colorado, bought last year, and through the contract manufacturer Catalent.

"There is a short-term challenge over the next six to nine months to make sure that we can manage the supplies that are out there," said David Lennon, president of Novartis' AveXis unit, in an interview.

"We feel comfortable where we are, but we'd love to have these other sites onboard to make sure we're really robust and don't face any risks of shutdowns or anything that could impact supply."

Limited supply has also kept Novartis from widening a program set up to make the gene therapy available free of charge to patients in countries where it's not yet approved. The "expanded access" scheme, which was launched in January, randomly allocates doses of Zolgensma for participating patients under the age of two with genetically confirmed spinal muscular atrophy.

This year, Novartis plans to distribute 100 doses through the lottery, which has been criticized as putting a child's life to chance.

"We obviously know that not everyone is happy with the program," said Lennon. "We're still considering what we might do, but we're open to making changes if it makes sense for the community and to meet the goals of the program."

Lennon said he hoped to expand the program as more manufacturing capacity for Zolgensma becomes available.

Novartis has committed upwards of $200 million to building out the site in Durham, which will employ about 400 staff by the end of the year.

Spanning 170,000 square feet, the facility will be used for both commercial Zolgensma manufacturing as well as to support clinical production of other gene therapies that Novartis is developing.

"This is as much an investment in the short term in building out our supply for Zolgensma, as it is for the long term to have the flexibility to deliver on a robust pipeline," said Lennon.

Novartis currently expects to treat about 100 infants every three months in the U.S. under Zolgensma's current label. But it's also working to expand the therapy's approval to treat older children over two using a spinal injection rather than an infusion.

That patient population is significantly larger and will test Novartis' ability to produce a steady supply of the drug, although the FDA has placed a partial "hold" on the study testing the new dosing.

Novartis' launch of Zolgensma is under significant scrutiny, both because of the $2.1 million price tag the drugmaker put on the therapy and due to a data manipulation scandal that engulfed the company last year.

Despite the high cost, insurers have largely covered treatment, leading to strong sales of Zolgensma in its first three quarters on the market.

See the original post:

With supply tight, Novartis readies gene therapy plant for production - BioPharma Dive

New Gene Therapies Institute Aims to Address Regulatory Barriers – HealthITAnalytics.com

February 20, 2020 -The Institute for Gene Therapies (IGT), a new advocacy foundation focused on policy issues surrounding gene therapies, recently launched with the goal of modernizing US regulatory and reimbursement framework for gene therapies.

According to IGT, the US health system currently spends about 85 cents of every healthcare dollar managing the symptoms of chronic diseases over a patients lifetime. With gene therapies, providers could alter patients non-functioning genes or replace absent ones, leading to long-lasting effects and potentially reshaping the way thousands of diseases are treated.

While traditional biologic and pharmaceutical medicines help manage the symptoms of disease over time, gene therapies target the cause of disease at the DNA level, creating lasting changes in the body. Some gene therapies are also designed to be one-time treatments that offer lifelong benefits.

IGT will work to educate stakeholders across the healthcare system about the potential for gene therapies to treat and cure common and rare chronic diseases, and advocate for policies that help ensure patients who need gene therapies can benefit from them.

Existing regulatory and reimbursement structures were established and adjusted over time to support pharmaceutical and biologic medicines, IGT noted, and need refining to accommodate the potential of gene therapies.

READ MORE: Data Mining Techniques Could Improve Cancer Gene Therapies

Many crippling conditions like Charcot-Marie-Tooth (CMT), which I was diagnosed with before the age of two take hold at a very young age, cut lives far too short or cause ongoing daily suffering, said Susan Ruediger, CEO of the CMT Research Foundation (CMTRF) and member of the IGT Patient Advocacy Advisory Council.

Like so many diseases, CMT currently has no cure. I am proud to stand with other leading patient advocates, members of the research community and companies that are developing gene therapies to help ensure patients can fully realize the benefits of these giant leaps toward treatments and cures.

The FDA has already approved four gene therapy products, and researchers are studying hundreds more in clinical trials for rare and common diseases, including many types of cancer, neuromuscular diseases, blood disorders and infectious diseases, and other conditions.

The growth of innovative research and product development in the field of gene therapy is exciting to us as physicians, scientists and regulators, FDA Commissioner Stephen M. Hahn, MD, said in a statement.

We understand and appreciate the tremendous impact that gene therapies can have on patients by potentially reversing the debilitating trajectory of diseases. These therapies, once only conceptual, are rapidly becoming a therapeutic reality for an increasing number of patients with a wide range of diseases, including rare genetic disorders and autoimmune diseases.

READ MORE: Genetic Sequencing Study Identifies 102 Genes Associated with Autism

The FDA has also released six final guidance documents on gene therapy manufacturing and clinical development of products. These documents incorporate input from stakeholders across the healthcare industry and make important strides in designing a modern structure for gene therapy development.

As the regulators of these novel therapies, we know that the framework we construct for product development and review will set the stage for continued advancement of this cutting-edge field and further enable innovators to safely develop effective therapies for many diseases with unmet medical needs, said Peter Marks, MD, PhD, director of the FDAs Center for Biologics Evaluation and Research.

Scientific development in this area is fast-paced, complex, and poses many unique questions during a product review; including how these products work, how to administer them safely, and whether they will continue to achieve a therapeutic effect in the body without causing adverse side effects over a long period of time.

IGT will being together experts across the healthcare community, including corporate leaders, patient advocacy groups, and academic and scientific stakeholders, to ensure health policies reflect the latest advancements in gene therapies. The institute will also work to remove barriers that limit patient access to these therapies and promote sustainable, long-term solutions.

Experts will learn more about the value gene therapies bring to patients, their families, and the healthcare system as a whole. IGT will help advance chronic disease treatments and get to the root cause of some of the most debilitating, expensive conditions that affect patients throughout their lives.

READ MORE: 77% of Americans Are Optimistic About Genetics Research, Potential

The incredible scientific advancements in this space present unique opportunities to directly improve and save the lives of patients suffering from debilitating diseases, said IGT Chairman, and former Congressman Erik Paulsen.

This is not some far-off future patients are already benefiting from the first FDA-approved gene therapies. But we need policy to move faster toward this new reality where we can treat the causes of many diseases. The Institute for Gene Therapies and our members believe unique regulatory and reimbursement structures need to be established, novel development pathways need to be embraced and new value-based arrangements need to be tested.

Read the original here:

New Gene Therapies Institute Aims to Address Regulatory Barriers - HealthITAnalytics.com

Bluebird’s gene therapy hits another delay, this time in the US – BioPharma Dive

Dive Brief:

Bluebird's commercial operations are just getting off the ground. In its latest earnings report, the Cambridge, Massachusetts-based biotech detailed how it has inked agreements with health insurers in Germany that should provide coverage for LentiGlobin, which is sold under the brand name Zyntegloin Europe, for up to 50% of eligible beta-thalassemia patients. Bluebird expects the first commercial patient to be treated before July.

Across the Atlantic, U.S. patients are looking at a longer timeline before LentiGlobin becomes available. Stifel analysts wrote in a note to clients that they don't foresee any stateside patients receiving the therapy commercially in 2020 "given what we anticipate will be a complicated negotiation process with payors."

Analysts at Raymond James, meanwhile, downgraded Bluebird to a "Market Perform" rating, writing that "execution issues on the regulatory, clinical and manufacturing side outweigh our support for the innovative drug products."

As Bluebird works through the latest delay in beta-thalassemia,it will also be preparing for an expanded research program in sickle cell. The company already intended to kick off a late-stage study in sickle cell patients with a history of vaso-occlusive crises in the first half of 2020. With Tuesday's earnings presentation, though, came plans to initiate a second late-stage study sometime this year, which will evaluate LentiGlobin's effects in about 18 children with sickle cell and elevated stroke risk.

A sickle cell approval, though a ways off, could boost Bluebird's bottom line. Beta-thalassemiais rarer in U.S. than other parts of the world, and certainly less common than sickle cell. According to estimates cited by the National Organization of Rare Disorders, roughly 3,300 U.S. patients have beta-thalassemiaversus the 100,000 who have sickle cell.

An expanded program could provide more evidence of LentiGlobin's benefit in this larger patient pool.Yet the updates don't seem to have alleviated investor concerns. Bluebird shares were down nearly 10% in late Wednesday morning, trading around $80 apiece.

"LentiGlobin in Sickle Cell Disease remains a bright spot, in our view, but with [late-stage studies] expected to get underway this year, we don't expect investor sentiment to change anytime soon," Stifel analysts wrote.

The investment bank models Zyntelgo bringing in $12 million worth of revenue in 2020 from the beta-thalassemia indication, increasing to $53 million in 2021 and $390 million by 2030. Conversely, it models $48 million in 2022 from the sickle cell indication, increasing to almost $2 billion by 2030.

More:

Bluebird's gene therapy hits another delay, this time in the US - BioPharma Dive

First patient undergoes Luxturna gene therapy on NHS – PharmaTimes

The NHS has reported treating its first patient with Novartis Luxturna (voretigene neparvovec) a revolutionary new gene therapy that can restore eyesight, as part of its NHS Long Term Plan.

The therapy is for those born with an inherited retinal disorder - Lebers Congenital Amaurosis (LCA) - who have poor sight which swiftly deteriorates, with many ultimately losing their vision completely in childhood.

The life-changing treatment for children and adults is the first in a new generation of gene therapies that can be directly administered to patients, in this case through an injection. Many patients in the trials have recovered their night time vision with the treatment.

Jake Ternet, patient at Moorfields Eye Hospital was the first in the UK to receive the treatment.

Professor Stephen Powis, NHS medical director, said:Loss of vision can have devastating effects, particularly for children and young people, but this truly life changing treatment offers hope to people with this rare and distressing condition.

Once again, the NHS is at the forefront of the genomic revolution with patients in England among the first to benefit from this new form of treatment a modern day miracle as part of the Long Term Plan.

Back in September last year, The National Institute for Health and Care Excellence (NICE) recommended the use of Luxturna on the NHS for certain patients with RPE65-mediated inherited retinal dystrophies in those with vision loss.

Read more here:

First patient undergoes Luxturna gene therapy on NHS - PharmaTimes

First Patients Begin Gene Therapy Treatment for Blindness through NHS – Interesting Engineering

Back in September, a breakthrough gene therapy was found to treat inherited retinal dystrophies. Now, people in the UK are being treated with it.

This gene therapy is meant for people who are born with retinal dystrophy. It happens when the patient inherits a faulty copy of the RPE65 gene from both parents. Babies lose sight as they grow older since this gene is crucial for providing the requirements that light-sensitive cells need to absorb light.

The trouble of sight starts with poor night vision and leads to complete blindness with the death of the current cells.

SEE ALSO:BLIND WOMAN PLAYS VIDEO GAME THANKS TO IMPLANT THAT JACKS DIRECTLY INTO THE BRAIN

NHS therapy is expected to halt sight loss and even improve vision in the process. In order to do this, working copies of the RPE65 gene is injected into the back of the eye. The copies are put inside a harmless virus and the virus penetrates the retinal cells.

After the virus is inside the nucleus, the gene provides the instructions to make the RPE65 protein. This provides a healthier vision.

The treatment is sadly only suitable for patients who have some vision remaining. It is expected to be beneficial to the children who have this eye disorder since it can stop sight loss before any permanent damage is done.

Matthew Wood is one of the first patients to receive the therapy. He started losing his sight as a child, and only had peripheral vision currently. His surgery was carried out by Professor Robert MacLaren.

In a BBC interview, MacLaren said, This is very exciting this is the first approved NHS gene therapy for an eye disease, but there are opportunities to use gene therapy to treat other diseases in the future, not only in the eye.

One downside of the treatment is the price point with 600,000. However, NHS England has stated that they have agreed on a discount with the manufacturer Novartis.

See more here:

First Patients Begin Gene Therapy Treatment for Blindness through NHS - Interesting Engineering

Spark R&D chief High exits in wake of Roche takeover – FierceBiotech

Spark Therapeutics co-founder and R&D head Kathy High has left the gene therapy specialist in the wake of its takeover by Roche. The Basel-based Big Pharma talked up its ability to cope with the loss of the R&D chief, pointing to the 450-person team High helped build to back up its confidence.

As a professor at Children's Hospital of Philadelphia (CHOP), High was involved in early efforts to give patients with an inherited vision loss disorder a functioning version of RPE65. The work led High to found Spark with Jeff Marrazzo, who became CEO of the biotech, and Steven Altschuler, the former president of CHOP, and ultimately to the approval of RPE65 gene therapy Luxturna.

High oversaw the development of Luxturna and the rest of Sparks pipeline. However, with Spark now part of Roche, High has decided to end her time in industry. Philadelphia Business Journal first broke the news, which Roche subsequently confirmed in a statement.

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Roches statement highlighted the central role High played in Luxturna, Sparks hemophilia A and B gene therapy candidates and its takeover of the biotech she co-founded. However, Roche also sought to downplay the risk that Highs departure could harm the prospects of the pipeline it acquired in the takeover of Spark.

Today, Spark has broad scientific knowledge and expertise in gene therapy, with the company now numbering more than 450 employees and continued growth expected in the future. This is why we dont expect any impact on the scientific expertise of our team or clinical programs. We expect that our scientific and clinical teams will continue their proven track record of innovation, progress and safety, the Roche spokesperson said.

Roche singled out a hemophilia A gene therapy as a Spark program that it remains committed to. The public commitment to the program follows a lull in news about the gene therapy. Spark shared phase 1/2 data late in 2018 and quietly began a lead-in study for a phase 3 trial last year. However, the gene therapy specialist said little about the program during its protracted takeover by Roche.

The period of radio silence now looks set to end, with Roche stating it will share an update on the program in due course. Roche will have to manage the program without the support of High, who is set to take some well-deserved time off and then will begin a new chapter in a sabbatical at a university, according to the Swiss Big Pharma.

Continued here:

Spark R&D chief High exits in wake of Roche takeover - FierceBiotech

Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease – The Motley Fool

Nearly 1.8 million Americans were diagnosed with cancer last year. Around the world, the total was close to 17 million. It's not surprising, then, that more than 700 biopharmaceutical companies have experimental cancer drugs in late-stage development.

Beta-thalassemia, on the other hand, is a rare disease that affects around 1,000 or so people in the United States. It's more prevalent in some countries but still impacts only one in 100,000 individuals.

You might expect one or maybe two biotechs could be developing therapies to treat beta-thalassemia. However, by my count, at least half a dozen companies have programs targeting the blood disorder. Why are a disproportionate number of biotechs scrambling to develop drugs for the same rare disease?

Image source: Getty Images.

Probably the main reason why a relatively large group of drugmakers are targeting beta-thalassemia is that the cause of the disease is straightforward. Understanding the why behind a disease is a critical prerequisite to treating it.

Beta-thalassemia is usually caused by a mutation in the HBB gene, which provides instructions on how to build beta-globin proteins. These proteins are part of hemoglobin, the protein in red blood cells that carries oxygen throughout the body. The HBB mutations that cause beta-thalassemia result in dysfunctional red blood cells that can't carry enough oxygen, which leads to patients experiencing anemia.

Another potential reason why biotechs are attracted to beta-thalassemia, though, is that it's not the only disease that is caused by mutations in the HBB gene. Sickle cell disease (SCD) is a related disease where HBB mutations cause red blood cells to form a sickle (or crescent) shape. These misshaped red blood cells can get stuck in blood vessels and cause multiple health complications, including anemia, infections, frequent pain, and heart problems.

While beta-thalassemia is rare, SCD is the most common genetic blood disorder in the U.S. It affects up to 100,000 Americans. SCD is even more prevalent in Africa, impacting up to 3% of newborns in some parts of the continent.

Drugmakers that identify a way to treat beta-thalassemia can be on the right track to target sickle cell disease as well. And with a much larger patient population, the market potential for successful therapies is greater.

One product has already been approved by the FDA for treating beta-thalassemia. Acceleron Pharma (NASDAQ:XLRN) developed luspatercept in collaboration with Celgene. In November 2019, Celgene won FDA approval for luspatercept in treating transfusion-dependent beta-thalassemia. Bristol-Myers Squibb (NYSE:BMY) closed its acquisition of Celgene a few weeks later and is marketing the drug under the brand name Reblozyl. Luspatercept is also in a mid-stage clinical study for treating non-transfusion-dependent beta-thalassemia.

Bluebird bio (NASDAQ:BLUE) won European approval for Lentiglobin in June 2019 for treating transfusion-dependent beta-thalassemia. Lentiglobin is a gene therapy that transplants cells with healthy HBB genes into patients. The biotech launched the therapy in Germany in January with the brand name Zynteglo. Bluebird plans to roll out Zynteglo in other key European markets later this year and should file for U.S. approval within the next few months.

Several biotechs are developing gene-editing approaches to treat beta-thalassemia. The company with the most advanced gene-editing program is Sangamo Therapeutics (NASDAQ:SGMO). However, there are some worries about ST-400, the experimental gene therapy that Sangamo is developing with Sanofi. In December 2019, Sangamo announced preliminary results from an early stage clinical study that, while showing promise, raised safety concerns.

CRISPR Therapeutics (NASDAQ:CRSP) and its big partner, Vertex Pharmaceuticals (NASDAQ:VRTX), are evaluating CTX001 in early stage clinical studies for treating beta-thalassemia and SCD. CTX-001 uses CRISPR gene editing, a different method than the zinc-finger nuclease (ZFN) gene-editing approach that Sangamo uses. CRISPR Therapeutics and Vertex reported promising preliminary results in December 2019 from both of its clinical studies.

Editas Medicine (NASDAQ:EDIT) is also using CRISPR gene editing to target both beta-thalassemia and SCD. The biotech hasn't advanced its experimental therapy to a clinical study in humans yet but plans to file for FDA approval later in 2020 to begin clinical testing. Editas thinks that its gene-editing approach is superior to the ones being taken by CRISPR Therapeutics and Sangamo.

Trailing the pack is Syros Pharmaceuticals (NASDAQ:SYRS). In December, Syros and Global Blood Therapeuticssigned a deal to work together to develop drugs targeting beta-thalassemia and SCD based on Syros' gene control platform. Instead of trying to directly edit the gene mutations, Syros' gene control therapies attempt to control the expression of genes through genomic switches in other parts of DNA. The biotech hasn't said how soon it will be able to advance to clinical testing with its experimental drug.

There are a couple of big problems for investors with so many companies chasing after the same rare disease. First, it's impossible to know which experimental therapies will be successful. Second, if multiple drugs win regulatory approvals, the competition could be so fierce that no product is a huge moneymaker.

It's also important to know that several of the products being developed hold the potential to cure beta-thalassemia. These therapies could wipe out the opportunities for drugs that aren't curative.

One solution to this investor's dilemma is to avoid all of the biotech stocks that are focused on beta-thalassemia. However, that's like throwing the baby out with the bathwater. I think that a better alternative is to invest in the big drugmakers with beta-thalassemia programs.

Bristol-Myers Squibb already has one FDA approval under its belt for Reblozyl. BMS also owns 5.3% of CRISPR Therapeutics and is partnering with Editas on developing gene-editing therapies targeting cancer. Vertex is partnering with CRISPR Therapeutics and owns 10.2% of the small biotech. Both BMS and Vertex stand to win with their beta-thalassemia drugs but also have plenty of other growth drivers.

Read more from the original source:

Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease - The Motley Fool

3 Cancer Treatment Stocks to Buy Right Now – The Motley Fool

There has been so much progress in treating cancer in just the past 10 years that it could make your head spin. Researchers have identified new ways to fight cancer -- and new ways to diagnose cancer more effectively, too.

Close to $150 billion will likely be spent on cancer drugs this year. This creates lots of opportunities for investors. But which cancer treatment stocks are the top picks right now? Here's why I think thatbluebird bio (NASDAQ:BLUE), Bristol-Myers Squibb (NYSE:BMY), and Intuitive Surgical (NASDAQ:ISRG) especially stand out.

Image source: Getty Images.

I recently include Bluebird on my list of the three best biotech stocks to buy for the next decade. This list was admittedly a stretch since it's impossible to accurately predict how any stocks will perform in the future. That's especially true for biotech stocks.

However, there are several reasons Bluebird could fly significantly higher. For one thing, the company recently lauched its first product, Zynteglo, in Germany. It will take a while for revenue to pick up for the gene therapy, which targets transfusion-dependent beta-thalassemia. But Bluebird expects to introduce Zynteglo in other key European markets later this year. It also plans for file for U.S. approval in the first half of 2020.

Zynteglo isn't a cancer treatment, but Bluebird has a couple of cell therapies that are. The company's partner, Bristol-Myers Squibb, should file for FDA approval of ide-cel in treating multiple myeloma, a type of blood cancer, this year. Bluebird and BMS are also collaborating on another promising multiple myeloma cell therapy, bb21217. I think that both drugs should become blockbusters if approved.

In addition, Bluebird has another rare disease drug in late-stage testing.The biotech should file for U.S. and European approvals for Lenti-D in treating cerebraladrenoleukodystrophy by late 2020.

Bluebird's partner, Bristol-Myers Squibb, ranks as one of the biggest cancer-focused drugmakers on the planet. Market researcher EvaluatePharma projects that the company's cancer immunotherapy will be the No. 4 top-selling drug in the world within the next few years. BMS has a rising star with its multiple myeloma drug Empliciti. And that's just the tip of the iceberg for BMS.

Thanks to its acquisition of Celgene in late 2019, BMS now has several other blockbuster cancer drugs in its lineup. Revlimid is the biggest moneymaker that BMS picked up in the deal. The company also now claims multiple myeloma drug Pomalyst and solid tumor drug Abraxane.

In addition, BMS's pipeline is bursting at the seams with potential blockbusters. The company expects to win FDA approval for liso-cel in treating relapsed or refractory large B-cell lymphoma by Aug. 17, 2020. We've already mentioned Bluebird's ide-cel, which BMS licensed.

Don't forget BMS's drugs outside the cancer arena. Blood thinner Eliquis should become the No. 3 best-selling drug in the world by 2024. Autoimmune disease drug Orencia continues to perform very well. BMS also hopes to win FDA approval for Celgene's ozanimod in treating multiple sclerosis next month.

You might be a little surprised to see Intuitive Surgical included along with two drugmakers as a top cancer treatment stock to buy right now. But Intuitive's da Vinci robotic surgical system is used extensively in treating prostate cancer, with 138,000 urological procedures performed with the system in the U.S. alone last year.

To be transparent, though, Intuitive's prominence in treating prostate cancer isn't the main reason why I included this stock. What I most like about Intuitive Surgical is its overall business model. The company basically uses a modern version of the old razor-and-blades approach. It makes money by selling robotic surgical systems but makes a whole lot more by selling replacement instruments, accessories, and providing services.

Intuitive Surgical's recurring revenue in 2019 stood at 72% of total revenue. That figure should continue to grow as the install base for da Vinci grows and as customers use the system for more procedures. Intuitive is also leasing more robotic surgical systems than ever before, which will boost recurring revenue even more.

Other companies hope to challenge Intuitive Surgical's dominance in the robotic surgical systems market. My view, though, is that this competition will be a good thing for Intuitive by expanding the market. I also think Intuitive Surgical's huge head start in developing an ecosystem supporting its technology gives it a solid moat.

Continue reading here:

3 Cancer Treatment Stocks to Buy Right Now - The Motley Fool

The Most Important Stock to Own Over the Next Decade – Nasdaq

I'll admit that I have no idea which stock will deliver the biggest returns over the next 10 years. If I had to guess, it would probably be a stock that hardly anyone has heard of right now. After all, the unknown tiny stocks have the most room to run.

But identifying the most important stock to own over the next decade is a different story. By my definition, the most important stock will be one that's most likely to have a profound impact on the greatest number of people.

There are several worthy candidates to get the nod as the most important stock for the 2020s. If I had to choose just one stock right now, though, it would be... Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL).

Image source: Getty Images.

We can look around today to see which trends are likely to matter the most over the next decade. Perhaps the most critical trend is the growing senior population across the world.

The U.S. Census Bureau projects that 2030 will be a turning point for the country with every member of the baby boomer generation over age 65. Nearly 25% of residents of the European Union will be at least 65 years old 10 years from now. Over 25% of Chinese citizens will be at least 60 years old by 2030. The percentages in other heavily populated Asian countries are even higher.

There lots of implications from these demographic trends. Hundreds of millions of people will have more time on their hands, for one thing. More importantly, though, the demand for healthcare products and services will almost certainly increase significantly.

Another key trend that should shape the next decade is the expanded role of artificial intelligence (AI). There has been a dramatic surge in the use of AI in recent years. Just ask your smartphone. But I expect the 2020s will usher in an era where AI is even more pervasive, from smarter apps to self-driving cars. This shift to increased use of AI will likely add fuel to the fire of another unstoppable technology trend -- the migration of apps and data to the cloud.

Speaking of trends that are already under way and should pick up momentum, how often do you use cash these days? If you're like most people, the answer is "at little as possible." The war on cash (i.e., the transition to digital payment methods) should intensify over the next decade.

Of course, there are other important trends that will impact many people in the 2020s. However, few will rival the significance that aging demographics, the increased prevalence of AI, and the war on cash will have.

Quite a few companies will play a role in at least one of these critical trends shaping the next decade. But a handful will be involved in all of them. I'd argue that Alphabet is the one company that covers the major trends from A to Z and that will make the biggest difference overall.

Let's start with aging demographics. Alphabet's apps, particularly Google Search and YouTube, are likely to be used much more frequently as older individuals have more leisure time. The more significant impact for the company, though, could be in healthcare.

Alphabet's Verily Life Sciences subsidiary is working with DexComon the development of its cutting-edge G7 continuous glucose monitoring (CGM) system. Verily is collaborating with several major drugmakers, including Novartisand Pfizer, on Project Baseline -- an effort to map a baseline of human health. This project could change how new drugs are developed and improve the quality of care provided to patients.

Another Alphabet subsidiary, Calico, has an even more ambitious goal: extending the human lifespan. There's no guarantee that Calico will unveil earthshaking developments over the next 10 years, but it might.

But I'd say that it is a certainty that Alphabet will be at the forefront of AI development in this decade. It already ranks as a leader in AI and has the resources to stay on top. Alphabet's Waymo unit expects to expand its fleet of self-driving cabs beyond the initial testbed in Phoenix, Arizona. It's partnered with Jaguar to develop the first fully self-driving car. And Waymo's self-driving big-rig trucks could move out of the testing phase in the not-too-distant future.

Image source: Getty Images.

Alphabet is also addressing two major trends at the same time by applying AI to healthcare. The company's DeepMind AI lab achieved a big breakthrough last year by using AI to predict a potentially fatal kidney disease 48 hours before it became critical. Alphabet's AI can even detect breast cancer more accurately than most human radiologists.

On top of all of this, Alphabet is also a major player in the war on cash with its Google Pay digital payment platform. Google Pay is available on more than 2.5 billion active Android devices worldwide. Alphabet even plans to launch online checking accounts for Google Pay users in 2020.

I don't expect Alphabet will be the best-performing stock of the decade. It's too big already. The good news, though, is that Alphabet's role in the key trends for the next 10 years should also lead to big stock gains.

Despite its $1 trillion market cap, Alphabet is still a growth stock. Its core businesses should power plenty of growth on their own. But I think that the company's healthcare, AI, and digital payment efforts will pay off in a major way, too. My view is that Alphabet is the most important stock to own over the next decade but also a winning stock to own over the next decade.

10 stocks we like better than AlphabetWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Alphabet wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of December 1, 2019

Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Keith Speights owns shares of Alphabet (A shares) and Pfizer. The Motley Fool owns shares of and recommends Alphabet (A shares) and Alphabet (C shares). The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Here is the original post:

The Most Important Stock to Own Over the Next Decade - Nasdaq

The view of quantum threats from the front lines – JAXenter

The future is here. Or just about. After a number of discoveries, researchers have proven that quantum computing is possible and on its way. The wider world did not pause long on this discovery: Goldman Sachs, Amazon, Google, and IBM have just announced their own intentions to embark on their own quantum developments.

Now that its within our reach we have to start seriously considering what that means in the real world. Certainly, we all stand to gain from the massive benefits that quantum capabilities can bring, but so do cybercriminals.

Scalable quantum computing will defeat much of modern-day encryption, such as the RSA 2048 bit keys, which secure computer networks everywhere. The U.S. National Institute of Standards and Technology says as much, projecting that quantum in this decade will be able to break the protocols on which the modern internet relies.

The security profession hasnt taken the news lying down either. Preparations have begun in earnest. The DigiCert 2019 Post Quantum Cryptography (PQC) Survey aimed to examine exactly how companies were doing. Researchers surveyed 400 enterprises, each with 1,000 or more employees, across the US, Germany and Japan to get answers. They also conducted a focus group of nine different IT managers to further reveal those preparations.

SEE ALSO:DevSecOps Panel Best DevOps Security Practices & Best Tools

An encouraging development is that 35 percent of respondents already have a PQC budget, and a further 56 percent are discussing one in their organisations. Yet, many are still very early in the process of PQC planning. An IT manager within a manufacturing company said, We have a budget for security overall. Theres a segment allotted to this, but its not to the level or expense that is appropriate and should be there yet.

The time to start preparing, including inquiring of your vendors readiness for quantum computing threats, is now. One of the respondents, an IT Security manager at a financial services company, told surveyors, Were still in the early discussion phases because were not the only ones who are affected. There are third party partners and vendors that were in early discussions with on how we can be proactive and beef up our security. And quantum cryptology is one of the topics that we are looking at.

Others expanded upon that, noting that their early preparations heavily involve discussing the matter with third parties and vendors. Another focus group member, an IT manager at an industrial construction company, told the group, We have third party security companies that are working with us to come up with solutions to be proactive. So obviously, knock on wood, nothing has happened yet. But we are definitely always proactive from a security standpoint and were definitely trying to make sure that were ready once a solution is available.

Talking to your vendors and third parties should be a key part of any organisations planning process. To that end, organisations should be checking whether their partners will keep supporting and securing customers operations into the age of quantum.

The data itself was still at the centre of respondents minds when it came to protection from quantum threats, and when asked what they were focusing on in their preparations, respondents said that above all they were monitoring their own data. One respondent told us, The data is everything for anybody thats involved in protecting it. And so you just have to stay on top of it along with your vendors and continue to communicate.

One of the prime preparatory best practices that respondents called upon was monitoring. Knowing what kind of data flows within your environment, how its used and how its currently protected are all things that an enterprise has to find out as they prepare.

SEE ALSO:As quantum computing draws near, cryptography security concerns grow

To be sure, overhauling an enterprises cryptographic infrastructure is no small feat, but respondents listed understanding their organisations level of crypto agility as a priority. Quantum might be a few years off, but becoming crypto agile may take just as long.

Organisations will have to plan for a system which can easily swap out, integrate and change cryptographic algorithms within an organisation. Moreover, it must be able to do so quickly, cheaply and without any significant changes to the broader system. Practically, this means installing automated platforms which follow your cryptographic deployments so that you can remediate, revoke, renew, reissue or otherwise control any and all of your certificates at scale.

Many organisations are still taking their first tentative steps, and others have yet to take any. Now is the time for organisations to be assessing their deployments of crypto and digital certificates so they have proper crypto-agility and are ready to deploy quantum-resistant algorithms soon rather than being caught lacking when it finally arrives.

Follow this link:

The view of quantum threats from the front lines - JAXenter

Why Quantum Computing Gets Special Attention In The Trump Administration’s Budget Proposal – Texas Standard

The Trump administrations fiscal year 2021 budget proposal includes significant increases in funding for artificial intelligence and quantum computing, while cutting overall research and development spending. If Congress agrees to it, artificial intelligence, or AI, funding would nearly double, and quantum computing would receive a 50% boost over last years budget, doubling in 2022, to $860 million. The administration says these two fields of research are important to U.S. national security, in part because China also invests heavily in these fields.

Quantum computing uses quantum mechanics to solve highly complex problems more quickly than they can be solved by standard or classical computers. Though fully functional quantum computers dont yet exist, scientists at academic institutions, as well as at IBM, Google and other companies, are working to build such systems.

Scott Aaronson is a professor of computer science and the founding director of the Quantum Information Center at the University of Texas at Austin. He says applications for quantum computing include simulation of chemistry and physics problems. These simulations enable scientists to design new materials, drugs, superconductors and solar cells, among other applications.

Aaronson says the governments role is to support basic scientific research the kind needed to build and perfect quantum computers.

We do not yet know how to build a fully scalable quantum computer. The quantum version of the transistor, if you like, has not been invented yet, Aaronson says.

On the software front, researchers have not yet developed applications that take full advantage of quantum computings capabilities.

Thats often misrepresented in the popular press, where its claimed that a quantum computer is just a black box that does everything, Aaronson says.

Competition between the U.S. and China in quantum computing revolves, in part, around the role such a system could play in breaking the encryption that makes things secure on the internet.

Truly useful quantum computing applications could be as much as a decade away, Aaronson says. Initially, these tools would be highly specialized.

The way I put it is that were now entering the very, very early, vacuum-tube era of quantum computers, he says.

More here:

Why Quantum Computing Gets Special Attention In The Trump Administration's Budget Proposal - Texas Standard

Quantum internet: the next global network is already being laid – The Conversation UK

Google reported a remarkable breakthrough towards the end of 2019. The company claimed to have achieved something called quantum supremacy, using a new type of quantum computer to perform a benchmark test in 200 seconds. This was in stark contrast to the 10,000 years that would supposedly have been needed by a state-of-the-art conventional supercomputer to complete the same test.

Despite IBMs claim that its supercomputer, with a little optimisation, could solve the task in a matter of days, Googles announcement made it clear that we are entering a new era of incredible computational power.

Yet with much less fanfare, there has also been rapid progress in the development of quantum communication networks, and a master network to unite them all called the quantum internet. Just as the internet as we know it followed the development of computers, we can expect the quantum computer to be accompanied by the safer, better synchronised quantum internet.

Like quantum computing, quantum communication records information in what are known as qubits, similar to the way digital systems use bits and bytes. Whereas a bit can only take the value of zero or one, a qubit can also use the principles of quantum physics to take the value of zero and one at the same time. This is what allows quantum computers to perform certain computations very quickly. Instead of solving several variants of a problem one by one, the quantum computer can handle them all at the same time.

These qubits are central to the quantum internet because of a property called entanglement. If two entangled qubits are geographically separated (for instance, one qubit in Dublin and the other in New York), measurements of both would yield the same result. This would enable the ultimate in secret communications, a shared knowledge between two parties that cannot be discovered by a third. The resulting ability to code and decode messages would be one of the most powerful features of the quantum internet.

There will be no shortage of commercial applications for these advanced cryptographic mechanisms. The world of finance, in particular, looks set to benefit as the quantum internet will lead to enhanced privacy for online transactions and stronger proof of the funds used in the transaction.

Recently, at the CONNECT Centre in Trinity College Dublin, we successfully implemented an algorithm that could achieve this level of security. That this took place during a hackathon a sort of competition for computer programmers shows that even enthusiasts without detailed knowledge of quantum physics can create some of the building blocks that will be needed for the quantum internet. This technology wont be confined to specialist university departments, just as the original internet soon outgrew its origins as a way to connect academics around the world.

But how could this quantum internet be built anytime soon when we currently can only build very limited quantum computers? Well, the devices in the quantum internet dont have to be completely quantum in nature, and the network wont require massive quantum machines to handle the communication protocols.

One qubit here and there is all a quantum communication network needs to function. Instead of replacing the current infrastructure of optical fibres, data centres and base stations, the quantum internet will build on top of and make maximum use of the existing, classical internet.

With such rapid progress being made, quantum internet technology is set to shape the business plans of telecom companies in the near future. Financial institutions are already using quantum communication networks to make inter-bank transactions safer. And quantum communication satellites are up and running as the first step to extending these networks to a global scale.

The pipes of the quantum internet are effectively being laid as you read this. When a big quantum computer is finally built, it can be plugged into this network and accessed on the cloud, with all the privacy guarantees of quantum cryptography.

What will the ordinary user notice when the enhanced cryptography of the quantum internet becomes available? Very little, in all likelihood. Cryptography is like waste management: if everything works well, the customer doesnt even notice.

In the constant race of the codemakers and codebreakers, the quantum internet wont just prevent the codebreakers taking the lead. It will move the race track into another world altogether, with a significant head start for the codemakers. With data becoming the currency of our times, the quantum internet will provide stronger security for a new valuable commodity.

Read the original here:

Quantum internet: the next global network is already being laid - The Conversation UK

U.S. Progress on AI and Quantum Computing Will Best China, Says CTO Michael Kratsios – BroadbandBreakfast.com

WASHINGTON, February 21, 2020 - U.S. Chief Technology Officer Michael Kratsios expressed confidence in the supremacy of the U.S.s artificial intelligence and quantum computing programs over Chinas, in a talk at the Hudson Institute on Thursday.

United States research on AI and quantum computing features the most highly cited papers, most investment by the private sector, and greatest government funding, he said.

This assertion challenges the Made in China 2025 Initiative, a 10-year plan that China issued in 2015, and which outlined 10 key tech industries in which China hopes to become a world leader.

Recent progress by the Chinese government in the field of high-speed fiber-optic broadband, AI and surveillance have fueled some analysts fears that the Chinese will hit their targets.

Kratsios laid out four key components of a winning tech strategy in which the U.S. excels: Leadership development, a low-regulatory environment, a belief in the power of the citizen workforce, and international engagement with allies.

Kratsios referenced two specific examples to bolster his argument. He mentioned how Trump committed to at least $200 million for STEM education last year, and how American corporations came more than matched that figure by donating $300 million.He also recounted the story that he said put America at the head of the pack in the quantum supremacy race. The story bears upon the uniting of resources invested by the U.S. government in the Quantum Lab at UC Santa Barbara with Googles subsequent acquisition of the lab and connection of that research team to its treasure trove of resources.

Its not a James Bond/Jason Borne crossover, but the concept of quantum supremacy is vital for national security, Kratsios said. America has only achieved it through a free market of ideas involving prudent government investing and private sector intervention.

Governmental funding and R&D are unique in that they fill the gaps that the private sector doesnt focus on.

Kratsios elaborated that the government tends to invest in early-stage, pre-competitive R&D which it expects the private sector to nurture and raise into a mature industry, such as in the case of the UCSB Quantum Lab.

Kratsios also gave made some comments on the proposals that the EU released Wednesday regarding AI and data. He characterized their approach to AI as values-based, and worried that they do not prioritize implementation.

Kratsios also found fault with the documents binary approach to classifying AI as high risk or not high risk, saying the report clumsily attempts to bucket AI-powered technology into two camps when there should be more spectrum and flexibility in the model.

Follow this link:

U.S. Progress on AI and Quantum Computing Will Best China, Says CTO Michael Kratsios - BroadbandBreakfast.com

Scientists Have Discovered a Brand New Electronic State of Matter – ScienceAlert

Scientists have observed a new state of electronic matter on the quantum scale, one that forms when electrons clump together in transit, and it could advance our understanding and application of quantum physics.

Movement is key to this new quantum state. When electric current is applied to semiconductors or metals, the electrons inside usually travel slowly and somewhat haphazardly in one direction.

Not so in a special type of medium known as aballistic conductor, where the movement is faster and more uniform.

The new study shows how in very thin ballistic conducting wires, electrons can gang up creating a whole new quantum state of matter made solely from speeding electrons.

"Normally, electrons in semiconductors or metals move and scatter, and eventually drift in one direction if you apply a voltage," says physicist Jeremy Levy, from the University of Pittsburgh. "But in ballistic conductors the electrons move more like cars on a highway."

"The discovery we made shows that when electrons can be made to attract one another, they can form bunches of two, three, four and five electrons that literally behave like new types of particles, new forms of electronic matter."

Ballistic conductors can be used for stretching the boundaries of what's possible in electronics and classical physics, and the one used in this particular experiment was made from lanthanum aluminate and strontium titanate.

Interestingly, when the researchers measured the levels of conductance they found they followed one of the most well-known patterns in mathematics Pascal's triangle. Asconductanceincreased, it stepped up in a pattern that matches one of the rows of Pascal's triangle, following the order 1, 3, 6, 10 and so on.

"The discovery took us some time to understand but it was because we initially did not realise we were looking at particles made up of one electron, two electrons, three electrons and so forth," says Levy.

This clumping of electrons is similar to the way that quarks bind together to form neutrons and protons, according to the researchers. Electrons in superconductors can team up like this too, joining together in pairs to coordinate movement.

The findings may have something to teach us about quantum entanglement, which in turn is key to making progress with quantum computing and a super-secure, super-fast quantum internet.

According to Levy, it's another example of how we're reverse engineering the world based on what we've found from the discovery of the fundamentals of quantum physics building on important work done in the last few decades.

"Now in the 21st century, we're looking at all the strange predictions of quantum physics and turning them around and using them," says Levy.

"When you talk about applications, we're thinking about quantum computing, quantum teleportation, quantum communications, quantum sensing ideas that use the properties of the quantum nature of matter that were ignored before."

The research has been published in Science.

See the rest here:

Scientists Have Discovered a Brand New Electronic State of Matter - ScienceAlert

Andrew Weatherall was uncompromising, pioneering, and a true alternative visionary – DJ Mag

One of the most respected, important and influential DJ/producers in our scene, Andrew Weatherall, has passed away. The tragic news was confirmed by his management in the afternoon of Monday 17th February in a short statement. He was 56.

A wry, sardonic character with a wicked sense of humour, Andrew was a legend of the underground scene. Uncompromising, pioneering, and a true alternative visionary, his influence on modern-day music cannot be underestimated.

Brought up in Windsor in Berkshire, west of London, Weatherall was a music fiend from the off. Thrown out of school, he was influenced by punk and post-punk and started playing in bands in his teenage years. When the acid house wave hit the UK in the late 80s he was at the centre of it, acerbically chronicling the nascent scene via the Boys Own fanzine and DJing at early London acid house club-nights like Shoom, Spectrum and The Trip.

Weatherall soon got into production, sitting in on sessions with Manchester hell-raisers the Happy Mondays, before getting the gig producing tracks on the new album by Primal Scream. A largely ignored Scottish indie band at that point, Primal Scream had taken to accompanying Weatherall on assorted DJ excursions, and when he remixed one of their songs into the dubbed-out, exultant Loaded prefixing the track with a We wanna get loaded and have a good time sample from 1966 Peter Fonda movie The Wild Angels it became massive in the clubs as much of the nations youth partied every weekend.

His work on Screamadelica was simply magnificent: his dubby, blissed-out takes on tracks like Come Together and Higher Than The Sun captured the UKs post-E zeitgeist immaculately, and led to the album topping most end-of-year Best Of lists on release in 1991. It won the first ever Mercury Music Prize in 1992, and is still cited as one of the finest albums ever in any genre.

As the most celebrated producer and remixer in the scene at the time (his work with My Bloody Valentine, One Dove and Saint Etienne was also justifiably lauded), Weatherall couldve cashed in at this point but instead took a left-of-centre turn. He set up Sabres Of Paradise with Jagz Kooner and Gary Burns (later both of The Aloof) most memorably producing astounding chill-out cut Smokebelch II that came out on Warp, followed by albums Sabresonic, Haunted Dancehall and Versus and also set up a label and club-night using the Sabres name. At Sabresonic he chiefly span techno and electro, providing a platform for talent from the emerging techno movement and a futuristic soundtrack for the more discerning London clubber.

After Sabres dissolved he set up Two Lone Swordsmen with Keith Tenniswood, a number of new labels Emissions Audio Output, Rotters Golf Club and then a number of experimental projects over ensuing years, including The Asphodells (with Tim Fairplay) and A Love From Outer Space (with Sean Johnston). He also produced the debut album by Bristol noiseniks Fuck Buttons.

A DJs DJ, Weatherall was frequently spoken about in hushed terms by the scenes cognoscenti as, pretty much, the Ultimate Don. Mixing up cosmic dub, skewed electro, trippy techno, raucous rockabilly and anything else he goddamn fancied, a Weatherall DJ set was always an out-there journey.

Over the years Weatherall was also a prolific lino-print artist; was artist in residence for book publishers Faber & Faber; was terminally a champion of many underground, leftfield artists; and one of the funniest and most down-to-earth people in the business. Genius is an over-used term, but it is undeniably apt when applied to Andrew.

Only last week he announced details of his new, low-slung spacey dub release, Unknown Plunderer, and was looking forward to a fruitful year which was to include DJ dates under the A Love From Outer Space brand.

Andrew was treated in Whipps Cross hospital in east London for a blocked artery, but sadly died on the morning of the 17th of February of a pulmonary embolism when the blood clot reached his heart. His death was swift and peaceful, according to the statement from his management company. The dance scene was united in grief at the passing of one of the absolute legends in the game.

View post:

Andrew Weatherall was uncompromising, pioneering, and a true alternative visionary - DJ Mag

Bleeding Edge Closed Beta Impressions – Attack of the Fanboy

Over the Valentines Day weekend Microsoft and Ninja Theory held a closed beta for Bleeding Edge that was available to all Xbox Game Pass members. I spent a solid twenty-hours playing it myself (and would have played more if I wanted to sleep on the couch), and came away feeling generally positive about the experience. Ninja Theory has poured a healthy helping of love and passion into Bleeding Edge, and it shows in every conceivable way. But, despite the fantastic aesthetic, confident style, and solid combat I couldnt shake this feeling that a key ingredient was missing.

The moment I loaded into the game on my PC I noticed the distinct art-style, a mix of Borderlands and Overwatch if I had to sum it up. Bleeding Edge has a cell-shaded aesthetic bolstered by crisp character-designs that each ooze personality. There is the metal-head Nidhogger with his flamethrower throat (how does he eat?), the spunky Gizmo and her large pink mechanical arm, and a damn robot snake piloting a corpse.Yeah, Kulev gives me the creeps, but I loved how wild his design was.

Each character on the roster had a distinct charm to them, and they were all meticulously animated and expertly voiced. Its the level of detail and care youd hope to see in a character-driven multiplayer game, especially after both League of Legends and Overwatch set the bar sky-high. The quality of the character design was evident in all aspects of the game, from the handful of emotes on offer, the quips and callouts made during matches, and the skillset associated with each brawler.

Zero Cools hovercraft/gaming chair came with an evasive double jump that allowed him to pop up and out of a fight while maintaining either his heals or attacks, whereas Cass had a combination of ranged and melee attacks, with gap-closer and disengage skills that allowed her to weave in and out of combat encounters. Gizmo had a jump pad she could use to either escape fights or join them, and Daemons stealth made me want to scream at my screen multiple times as the sneaky bastard appeared out of nowhere to ruin my day. No two characters felt similar, which is what youd hope to see in a game like this.

This confident design bleeds (heh) into every other aspect of the game. David Garcia has cranked out yet another exceptional soundtrack, after his stellar work in Hellblade, and it elevates the future-anarchist tone of the title. The menus have this street art/graffiti vibe to them that perfectly balances form and function, and the cosmetic upgrades for the hoverboard alone had a variety of wild options to unlock. Bleeding Edge absolutely nails it in the audio and visual departments, giving the game a clear identity that allowed me to more easily mesh with the title. This isnt some soulless attempt by Microsoft and Ninja Theory to emulate other similar character-driven multiplayer arenas, and the passion will no doubt help endear the game to the masses.

Gameplay also sets Bleeding Edge apart from the pack: its an objective-based, competitive, predominately melee brawler. Considering Ninja Theorys track-record, this shouldnt shock many. The question going into the beta, however, was how well their brand of gameplay would translate into a multiplayer environment. For the most part, it works out rather well.

Combos are simple, and the game largely uses auto-targeting (though, you can hard lock onto an enemy with the press of a button). Whats here worked, and felt punchy. Mostly. Ranged characters could sometimes struggle without lock-on due to the auto-targeting cycling between shots, but nothing that couldnt be overcome after some familiarization. That, and it was not difficult to find yourself stun-locked. Despite having all my evade charges Id often find myself unable to escape an enemy combo, despite the tutorial making it clear I should. Those moments felt cheap, but Id be lying if I said I didnt mind being on the delivery end of that relationship.

There were only two game-modes on offer: Capture and Power Collection. Capture works as you assume it does: capture the activated capture-point and defend them from the opposing team; first team to reach 600 points wins. Power Collection was rather straight-forward in design: collect power cells located around the map during one phase, then bank them at a set point during the next. Rinse, repeat, hopefully win. Theyre not exactly novel on paper, but the creative map design sets them apart from similar titles. For example, on one map the capture points rotated around the area on a stream that would occasionally pass through electrical gates, forcing constant movement around the map. Another map had a barrage of missiles that would launch every so often, usually targeting an active control point, giving the attacking team a chance to seize the objective once the fireworks had concluded.

Overall, I walked away from the beta feeling like all these pieces did an excellent job clicking together, making Bleeding Edge both familiar and unique. Its already a polished, well-realized title with a personality all its own. But, I felt this weird itch at the back of my brain, like something was missing. You know the sensation: when you walk into room you know well, but something minor is off. Is it the missing family portrait that once sat on the mantle? Is the cat not in their usual spot on the recliner napping? It was this nagging feeling I couldnt shake all weekend, despite enjoying my time with the Bleeding Edge beta.

Im not the only person who felt this way, and even now the subreddit is littered with posts offering up various suggestions. Something about Bleeding Edge feels off, like its missing the final bits of a 1000-piece puzzle. Was it the lack of music during matches? Perhaps the omission of an in-game announcer? Do characters need more skill-based combos? Did the matches drag on too long? Maybe its the maps feeling too large for eight players? Healing felt a bit too powerful, so it could be that. Its these little quibbles that added up slowly as I played, and kept the game from fully clicking with me. I loved what I played, but I never felt an underlying drive to continue playing; that one more match factor.

There is a key ingredient missing here, but its hard to put my finger on. Maybe its as simple as addressing those little nits I listed above, maybe its just shortening the matches and having a proper ranked mode? There is something about the Bleeding Edge beta that, despite all the obvious love and care put into it, is keeping it from truly exploding into the zeitgeist. There is another beta weekend in March, and Ill play the game again then to see if I can figure out whats not syncing with the title. Bleeding Edge is a fantastic game, but what it needs to catapult into the limelight isnt quite here yet.

- This article was updated on:February 17th, 2020

Go here to read the rest:

Bleeding Edge Closed Beta Impressions - Attack of the Fanboy

OPINION: If face masks are the new normal, why are we acting like everything’s business as usual? – ABS-CBN News

January was a long month. 2020 took us into its thorny arms withthe impending threat of World War 3, the Australian bush fires, the passing of Kobe Bryant, and a host of other catastrophic events that made Biblical apocrypha look plausible.

And while we didnt get a seven-headed beast rising up from out the sea, we did get something pretty closethe eruption of Taal and days of ashfall, and the coronavirus. Thats like two for the four horsemen of the apocalypse, if were still stretching the Revelation metaphor.

These calamities prompted, well, widespread panic, and the harried procuring of face masksspecifically the N95 model, the kind you see on doctors and nurses on a normal day. The Mercury Drug near my place was small, so it wasnt long lines I saw but an anxious throng of people pooling up at the counter as I queued up. Owning this commodity was life or death. I mean, we're talking about the unofficial successor of SARS, and a condition in which microscopic volcanic glass shreds your lungs up from the inside.

I had heard stories of doomsday opportunists buying masks in bulk and reselling them for exorbitant prices, taking advantage of shortages they themselves caused. But it wasnt long until everybody got a face mask and, despite the dystopic mood that plagued (pun tragically intended) our day-to-day lives, we carried on, faces covered up and fears slightly assuaged.

And then it became... a look. It seemed as though the face of the city had changed, and the N95 became a wardrobe staple. The sight of crowds suddenly appeared a little unfamiliar with noses and mouths obscured. Surgical masks became neutral pieces, compatible with business formal and smart casual. It wasnt long before I started seeing custom face masks in different colors, shapes and prints, some even with tastefully placed filters.Look at this goddamned Instagram postof a face mask hooked up to a mason jar with leaves in it.

A friend told me hed go to the office and see people comparing face masks. His was a model from Airinium, a face mask company designed to keep you respitorally healthy in any urban environment,whose website describes its productas one that offers a personalized fit for optimal comfort and with such sleek design that it will enhance your everyday outfit. Masks come in quartz grey, onyx black, pearl pink, and other designs.

"Warcore" is a termcoined by VOGUEto describe a fashion movement inspired by the aesthetics of armed combat. You'll know it when you see it: military fatigues, assault vests, glossy black boots designed for both runway-rocking and curbstomping coppers. While sartorial items like camo pants and wearing your Doc Martens to protests isn't new, warcore is different. According to Mr Porter, "'Warcore' is something thats come off the back of the utilitarian trend thats been doing the rounds, but is a bit more aggressive. What this means is super-thick, anti-stab fabric, waistcoats in the style of bulletproof flak jackets, buckled belts and sportswear layered over more sportswear."

A friend told me hed go to the office and see people comparing face masks. His was a model from Airinium

The proliferation of face masks seems to fall squarely into the trend of warcore. While we've seen the item in non-conflict settingsfor example, Kpop stars hiding their faces when they show up at the airportthe face mask constantly shows up on our feeds, in a news cycle that perpetually reports violence on a global scale. Hong Kong protestors wear face masks to defend against gas attacks and the scrutinizing eye of a growing surveillance state. Mass movements over the last decade have been encapsulated in at least one picture of a triumphant rioter with a bandana over their face.

Its comforting though that warcore seems to take on a more anti-authoritarian edgeits proponents looking more like Banksy caricatures than fascist pigs. Entertain the thought, though. Jawnz lords stepping up to the plate when the class war reaches its boiling point, throwing molotov cocktails at the boys in blue while donning Virgil Ablohs.

But this isntreallyabout warcore. My gripe is not high fashion's tendency to take the look of the streets and luxify it for haute couture consumption. That's a whole different conversation. We can't stop people from beautifying things we're already wearing for specifically utilitarian purposes. There is an argument for letting humans be human, and allowing them to find art and beauty in disaster. As VOGUE themselves put it: If fashion people are quick to adopt a trend or idea, the best we can hope is that this form of visual resistance lines up with actual resistance, actual political change. The clothes wont protect us and our freedoms, but the people inside them might."

We can't stop people from beautifying things we're already wearing for specifically utilitarian purposes. There is an argument for letting humans be human, and allowing them to find art and beauty in disaster.

And as much as I'd like to posture disdain at how capitalism commodifies our anxieties, I really freaking want an Airinium mask. That shit looks fly as hell, and I too am enchanted by the idea of looking like a decked-out badass in a riot, even though a record of perfect behavior in school leaves me completely unprepared for the event I tussle with a trained law enforcer.

What actually stresses me out is the omnipresence of the commodity, warcore aside. The face mask has, whether we notice it or not, shifted the way we go about our day-to-day affairs. There are times when I've gone out while wearing a face mask to catch up with an old friend, deadset on battling loneliness while suiting up for invisible contagions. For a period of a couple of weeks, my IG stories were chock full of the gear, people posting face mask selfies while making peace signs. I'm sure that shit is normal in South Korea, especially for bracing against the winter season's dry winds, but it ain't normal here. What used to be normal for motorcycle drivers and medical attendants became a wardrobe staple for the zeitgeist.

I look at the face of the city and its nose and mouth are erased. All I see are eyesnever shifty or panicked, but just resigned to the way of things. It's like a dystopian sci-fi movie, the kind where the hoi polloi lug around ramshackle cyborg prosthetics while doing normal shit like bargaining at the neon-lit wet market. Or like, a dieselpunk film, where Mad Max types sport war paint while doing non-desert raid related activities.

What I mean to say is, there is a clear dissonance between how our dystopia looks and how we feel about how it looks. I would feel more comfortable and sane if we, the general populace, were more aware of the dystopic quality of the present since we're already wearing its threads. And by that I don't mean using our coronavirus hysteria as an excuse to stoke anti-Chinese sentiments. I mean, we shouldn't be going to work. I mean, we shouldn't be acting like our days must go on as usual despite these disasters. The eruption of Taal and the spread of the coronavirus came at us full swing in that single hellish month and messed up our collective psycheshouldnt we be more anxious?

And even though these events are being managed in varying degrees of efficacy, shouldnt we be acting more like death is around the corner, what with all the other terrible shit happening in the world everyday? I come to work looking like I'm on the run from Big Brother, and sit down to discuss content output. Like this article. Sometimes, that distorted sense of (ab)normalcy is easy to take. Sometimes, it's hard to breathe.

Go here to read the rest:

OPINION: If face masks are the new normal, why are we acting like everything's business as usual? - ABS-CBN News

Italy under the coronavirus attack: the return of the Plague Spreaders – Resilience

This post is about how Italy is reacting to the diffusion of the COVID-19 epidemics that arrived during the past few days in the Northern regions of the country. Among other effects, it generated a wave of hate on social media comparable to what had happened in Italy at the time of the bubonic plague, in Milano during the 16th century. That epidemics was widely attributed to evil plague-spreaders (untori), so much that a column of infamy shown above was erected to commemorate the execution of two of them.

Alessandro Manzoni (1785-1873) was one of the greatest Italian writers in history, known also outside Italy for his novel The Betrothed (I Promessi Sposi). Manzoni lived well before the existence of social media and, in his times, even newspapers were something new. But he was a fine observer of society and I would go as far as to say that he could be seen as one of the early creators of the science we call today memetics, the science of the diffusion of ideas (memes).

In The Bethroted and the later historical essay A History of the Column of Infamy, Manzoni told the story of the bubonic plague that struck Milano in 1629-1631. Hitting a society already weakened by a previous famine and by the disaster of the 30 years war, the plague took a toll of nearly 50% of the population. Those who experienced it fell prey to a delusion that led them to think that the plague was caused by the actions of evil people termed the untori, a well-known word in Italian but hard to translate into English. Literally, it means greasers and it refers to people who would spread poisonous substances over people and things in order to spread the infection the term could also be translated as plague-spreaders. The greasers were supposed to perform their evil deeds because they were possessed by the devil, maybe for political or economic gains, or simply because they were evil.

The novel and the essay by Manzoni provide an amazing account of how the untori meme spread among the citizens of Milano to the point that several innocent people were lynched in the street. Others were accused, tortured, and forced to confess their pretended crimes. Then they underwent trials that were nothing more than witch-hunts (in this case, greaser-hunts). Several were executed and, in one case, a column (The Column of Infamy) was erected to commemorate the execution of two of them.

In this story, we can immediately recognize our world: the existence of the evil greasers is a classic example of fake news. The aggressive reaction of the public is something we see every day on our social media where, fortunately, people are not lynched for real (so far). An especially interesting touch by Manzoni is the fictional character of Don Ferrante, a mediocre Milanese intellectual who finds a moment of popularity when he starts declaring that the plague doesnt exist or that, in any case, it is not contagious rather, it is the result of a weird astral conjunction. We recognize in this character some of our modern climate-deniers who maintain more or less the same thing about climate change. Eventually, Don Ferrante catches the plague, too, but up to the last moment he keeps denying that it exists. He dies cursing the stars!

Certain things are timeless and dont depend on the existence of the Internet or even of the printed media. But, today, for sure the Web can spread hate and fake news at an unbelievably fast speed. In Italy, the COVID-19 epidemics arrived just a couple of days ago and the social media are already exploding in a wave of hate against the current untori, in this case supposed to be the Greens, the Government, the Communists, Immigrants, Africans, and in general the do-gooders (in Italian, buonisti), supposed to have done nothing to avoid the spreading of the pandemics when it was still possible to stop it.

Overall, the coronavirus is a threat that cant be even remotely compared to the bubonic plague, but the reaction of many people is about the same: they want blood. They are stating that clearly in their comments (just one example I read yesterday: I am a mother, if my children catch the coronavirus, you Communists will die first!). Curiously, these are often the same people who accuse climate scientists of being alarmists.

At the beginning, the Italian Right seemed to be willing to ride the issue and use it as a tool to make the current left-center government fall. But it seems that the leaders are now backtracking and trying to control their overexcited followers. So, cool heads may still prevail and we wont see people lynched in the street accused of being untori (but we did see physical attacks on people looking Chinese fortunately without victims, so far). The situation is rapidly evolving and well see what happens in the coming days.

One thing thats already clear, anyway, is that the current political system, polarized as it is, makes it impossible to face emergencies without exaggerating the threat or, conversely, denying it. In every case, one of the two sides is tempted to ride the issue to gain traction in the political game. Thats a disaster that leads nowhere. We are seeing it well for climate change and not just in Italy: with this decisional system, we cant control anything. We can only hope for the best (a concept expressed in Italian as trusting lo stellone the great star of Italy).

Image: Colonna Infame (Column of Infamy) via Ugo Bardi

See the original post here:

Italy under the coronavirus attack: the return of the Plague Spreaders - Resilience

Looking forward to being with my great friends in India: US President Donald Trump – Deccan Herald

President Donald Trump has said that he was looking forward to being with his "great friends" in India as he retweeted a video in which his face was superimposed on the hit movie-character Bahubali, showing him as a great saviour.

Trump will arrive in India on Monday on a two-day visit at the invitation of Prime Minister Narendra Modi. He will be accompanied by a high-level delegation including First Lady Melania Trump, daughter Ivanka, son-in-law Jared Kushner and a galaxy of top American officials.

"Look so forward to being with my great friends in INDIA!" Trump tweeted on Saturday.

Along with the tweet, Trump shared an 81-second video by a Twitter account identified as "Sol" with the handle Solmemes1.

"To celebrate Trump's visit to India I wanted to make a video to show how in my warped mind it will go... USA and India united!" the handle Solmemes1 tweeted in the original post with the video.

Trump appears as a great saviour, in the short animated clip, riding on a chariot with First Lady Melania. A few stills later, Trump is seen riding a horse carrying on his soldiers his son Donald Junior and daughter Ivanka.

Later, he is welcomed by Prime Minister Modi in a village setting. Hundreds and thousands of people are seen welcoming Trump in the video.

"This week Trump will visit India and in celebration, I have created a new meme for the occasion... You few, who are my patrons, get to see it first!" Sol told viewers on subscription content service Patreon on Saturday.

A few hours later, Trump retweeted the video.

In the Twitter description, Sol describes herself as "award-winning master memetics, professor of memology at University of GFY, my views are my own and not associated with real life."

The video, which ends with "USA and India United", went viral after Trump retweeted it. In a few hours, it was seen by more than ten lakh people.

Sol in one of her previous posts, dated January 23, writes she was inspired by a video of Bahubali sent to her by a friend, which is the story of 'good defeating evil.'

This inspired Sol to create her first Bahubali-theme meme. The video is titled "Jiyo Re Baahu Trump", in which the First Lady is seen wearing a saree. "Jiyo Re Bahubali," is the theme song of the video.

Sol's posts show she is an admirer of the President and the First Lady.

Her January 23 video was released at the peak of Trump's impeachment proceedings. In the video, Trump is seen being greeted by an elephant, who bears the logo of the Republican Party.

Towards the end of the video, Trump is seen riding the elephant and putting on fire the effigy of "Raavan" marked as "D" in a big circle representing the opposition Democratic Party.

An arrow is given by warrior Modi to the First Lady, who then passes it on to Trump before he lights the effigy.

Trump's visit to India provides an opportunity for the two countries to improve their bilateral relationship and strengthen strategic interests, say senior officials.

After Barack Obama, Trump is the only other US President to visit India in his first term.

Issues expected to be discussed during the visit include an open Indo-Pacific, reduced trade barriers, boost to counter-terror cooperation and mitigating Indian concerns over H-1B visas.

"President Trump has been the best friend of India amongst all US Presidents. He loves Indians and Indian-Americans. Indian Americans nationwide love him as much," Al Mason, advisor to Global Real Estate Investments, Education Institutions and Hospitals, told PTI.

"How else do you explain 60,000 Indian-Americans attending his 'Howdy, Modi!' rally with Prime Minister Modi in Houston, not to overlook the fact that billion-plus Indians in India love President Trump too," he said, referring to Trump and Modi sharing the stage in September in Houston at a massive rally of Indian-Americans called "Howdy, Modi!".

Modi and Trump are set to share the stage on Monday for "Namaste Trump," event which roughly translates as Hello Trump" in Ahmedabad.

The president, who arrived at the White House following four days of hectic political campaigning in the western parts of the country, had no public engagements on Saturday.

Trump did not go for a round of golf, which is normally the case for him on a bright sunny weekend day in Washington.

Read the original:

Looking forward to being with my great friends in India: US President Donald Trump - Deccan Herald